Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Conventional systemic therapies
11 evidence topics · 6 sources
Methotrexate: guideline recommendations on use, comparative efficacy, dosage, and folate supplementation
Methotrexate efficacy in randomized trials: PASI 75 versus placebo and adalimumab
Methotrexate oral solution: FDA-approved indication, dosage, boxed warning, and hepatotoxicity in psoriasis
Methotrexate: guideline statements on dose, principal adverse reactions, and myelosuppression
“The recommended initial and maintenance dose is usually 15 mg MTX once weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most important adverse drug reactions (ADRs) in association with MTX therapy are mucositis, MTX‐induced pneumonitis, hepatotoxicity, and myelosuppression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Another rare, but serious adverse event of MTX therapy is myelosuppression with an estimated prevalence of <1% (7/100,000 patient years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cyclosporine: guideline recommendations and PASI response rates
Cyclosporine: FDA-approved indication, dosage, and boxed warning for psoriasis
Cyclosporine nephropathy and malignancies in psoriasis
Acitretin: guideline recommendation and PASI 75 response
Acitretin: FDA-approved indication, dosage, and pregnancy warning
Network meta-analysis: methotrexate and ciclosporin compared with biologics, apremilast, and placebo
“Infliximab, adalimumab, ixekizumab, and risankizumab were more effective than methotrexate (infliximab: RR 2.86, 95% CI 2.15 to 3.80; adalimumab: RR 3.73, 95% CI 2.25 to 6.19; ixekizumab: RR 2.05, 95% CI 1.43 to 2.94; risankizumab: RR 2.37, 95% CI 1.59 to 3.54).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of a lower risk of SAEs for participants on methotrexate compared to placebo (RR 0.15, 95% CI 0.03 to 0.72).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our confidence in the results for non‐targeted systemic treatments is limited due to concerns regarding study conduct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote